Seres Therapeutics to Present at Three Upcoming March Conferences

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences:

  • Chardans Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY.
  • Cowen and Company 39th Annual Health Care Conference: a corporate overview will be presented on Monday, March 11th at 11:20 a.m. ET in Boston, MA.
  • Oppenheimer 29th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 19th at 11:30 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the Investors and Media section of Seres website. A replay will become available approximately one hour after each event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent C. difficile infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit

IR or PR Contact:
Carlo Tanzi, Ph.D., Seres Therapeutics,
Vice President, Investor Relations and Corporate
[email protected]


Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.